Business Results and Finance
IR Information Office
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2018
FY2017, ending March 2018, H1 Presentation
Year Ending March 31, 2018 Results of 2nd Quarter Settlement of Accounts Supplementary Material(Apr.1 to Sep.30 2017)
About Joint Promotion of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko"
About Marketing Approval for Infliximab BS for I.V. Infusion 100mg "AYUMI"
A Message from Management
Midium-term Business Plan
Highlights of Financial Results
Major Financial Indicators
Short Reports of Financial Results
Briefing Session Information
Return to Shareholders/Dividends
Coverage by Analysts
Back to Top
Copyright 2014 Nichi-Iko Pharmaceutical Co., Ltd. All Rights Reserved.